The impact of the US priority review voucher on private-sector investment in global health research and development.

by Andrew S Robertson, Rianna Stefanakis, Don Joseph, Melinda Moree
Published 2012-01-01

Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.

by Rianna Stefanakis, Andrew S Robertson, Elizabeth L Ponder, Melinda Moree
Published 2012-01-01